Answers are grounded in this paper and cite their sources.
Retrospective study reports efficacy and safety of long-term hypomethylating agents in myelodysplastic syndromes, highlighting clinical therapeutic maintenance.
To evaluate the efficacy and safety of hypomethylating agents (HMA) in patients with myelodysplastic syndromes (MDS) .
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: